Biotechs focusing on long non-coding RNAs have proliferated in recent years, and another new company announced its launch early Tuesday. NextRNA Therapeutics came out of stealth with $56 million in financing — $9.3 million from a seed financing and $46.8 million from a Series A — as it looks to
A new biotech out of Dana-Farber wants to join the long non-coding RNA party, with help from Bob Langer
![A new biotech out of Dana-Farber wants to join the long non-coding RNA party, with help from Bob Langer A new biotech out of Dana-Farber wants to join the long non-coding RNA party, with help from Bob Langer](https://endpts.com/wp-content/uploads/2022/03/Dominique-Verhelle-NextRNA-tile-scaled.jpg)